VIGL: Vigil Neuroscience Inc. Price to Net Income Growth Ratio
Geopolitical tensions are restricting scientific exchange and reagent logistics, creating risks for drug certification. However, patents on microglia activation and a debt-free balance sheet strengthen the position of Vigil Neuroscience (VIGL), while strict adherence to FDA standards for biomaterial disposal minimizes environmental risks. The company's current PEG valuation demonstrates price dynamics, with the indicator holding around 0.00.
Metric breakdowns and analytics for Vigil Neuroscience (VIGL)
- price and consensus price forecast:
- market capitalization information:
- book capitalization data:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Vigil Neuroscience|VIGL - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio vigilneuro.com|VIGL - Company Aggregate Debts|Debts to Book Value Vigil Neuro|VIGL - Company Long-Term Liabilities|Company Short-Term Debts Vigil Neuroscience|Intermediate Coverage Ratio vigilneuro.com
- net income and valuation ratios data:
VIGL - Company Net Income|Expected Net Profit Vigil Neuroscience|VIGL - Price to Earnings Ratio|Market Cap to Projected Earnings vigilneuro.com|VIGL - PEG Multiple|Enterprise Value to EBITDA Ratio Vigil Neuro|VIGL - Operating profit EBITDA|Net earnings per share for the last four quarters Vigil Neuroscience|VIGL - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months vigilneuro.com|VIGL - Earnings per share growth in current year|Projected earnings per share growth rate for next year Vigil Neuroscience
General company analysis:VIGL - Vigil Neuroscience Inc.
The assessment of the margin of safety for Vigil Neuroscience (VIGL) is based on the ratio of the price-to-earnings multiple to its growth rate, where a value below one signals a fundamental undervaluation of the asset. By analyzing the PEG ratio, an investor determines the capitalization efficiency of the expansion rates of this biotech expert, which develops innovative therapies for neurodegenerative diseases and Alzheimer's to restore brain immunity.
Who Vigil Neuroscience competes with
Growth-Adjusted Market Cap to Net Income Biogen Inc|PEG Multiple NBIX (Neurocrine Biosciences Inc)|Price to Net Income Growth Ratio Regencell Corp|Axsome Therapeutics - PEG Multiple|Growth-Adjusted Market Cap to Net Income acadia-pharm.com ACAD|Xenon (XENE) - Price/Earnings to Growth Ratio|VKTX (Viking Therapeutics Inc) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple SUPN|CPRX: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Denali Therapeutics (DNLI)|harmonybiosciences.com - Growth-Adjusted P/E Ratio|PEG Multiple BHVN (Biohaven)|Amylyx Pharmaceuticals Inc (AMLX) - Price to Earnings Adjusted for Growth Rate|TRVI: Price/Earnings to Growth Multiple|PRAX - PEG Multiple|Anavex Life Sciences (AVXL) - Price/Earnings to Growth Ratio|ceribell.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Prothena Corporation plc|Price to Earnings Adjusted for Growth Rate Alector Therapeutics ALEC|Price/Earnings to Growth Ratio Annexon Inc. (ANNX)|Growth-Adjusted Market Cap to Net Income omeros.com|PEG Multiple NGNE (Neurogene Inc.)|ACIU - Price/Earnings to Growth Multiple|Voyager Therapeutics, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income Neumora NMRA|SCLX: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tevogen Bio Inc. (TVGN)|Price/Earnings to Growth Ratio Alpha Cognition Inc|Growth-Adjusted P/E Ratio CGTX (cogrx.com)|PEG Multiple IKT|Price/Earnings to Growth Multiple Cassava Sciences Inc SAVA|PEG Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Price to Earnings Adjusted for Growth Rate|VTGN: Price/Earnings to Growth Multiple|OVID: Price/Earnings to Growth Ratio|ABOS: PEG Multiple|CRVO - Growth-Adjusted Market Cap to Net Income|ATHE (Alterity Therapeutics Ltd.) - PEG Multiple|CLNN - Price to Net Income Growth Ratio|Price/Earnings to Growth Ratio PepGen Inc. (PEPG)|Price/Earnings to Growth Ratio JUNS (jupiterneurosciences.com)|Price/Earnings to Growth Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Growth-Adjusted P/E Ratio|Grace Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Firefly Neuro|KLTO (anewmeds.com) - Price/Earnings to Growth Multiple|NeuroSense Therapeutics Ltd. (NRSN) - PEG Multiple|Price/Earnings to Growth Ratio Reviva Pharmaceuticals Holdings, Inc.|MTVA: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio NeurAxis, Inc (NRXS)|HSDT - Price to Earnings Adjusted for Growth Rate|Passage Bio - Price/Earnings to Growth Multiple|Neuphoria Therapeutics, Inc. - Price/Earnings to Growth Ratio|Minerva Neurosciences, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income Athira Pharma Inc ATHA|ADXN: PEG Multiple|Price to Net Income Growth Ratio Alzamend Neuro ALZN|CYCN (Cyclerion Therapeutics Inc.) - PEG Multiple|Protagenic (PTIX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Pasithea Therapeutics (KTTA)|Price/Earnings to Growth Ratio CRGT (cortigent.com)|Avenue Therapeutics, Inc - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BCLI|CARA - Price/Earnings to Growth Ratio|CHRO (chromocell.com) - Growth-Adjusted P/E Ratio|ELYM: PEG Multiple|Price to Earnings Adjusted for Growth Rate Intra-Cellular Therapies, Inc. (ITCI)|Price/Earnings to Growth Multiple LBPH|PEG Multiple Marinus Pharma|Price/Earnings to Growth Ratio NKGen Biotech, Inc. (NKGN)|NRBO (neurobopharma.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Sage Therapeutics SAGE|Synaptogenix Inc. (SNPX) - Price to Earnings Adjusted for Growth Rate|TRVN - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Anew Medical Inc. WENA|CERE: PEG Multiple
